Skip to main content
NCBI home page
The BMJ logoLink to The BMJ
editorial
. 1995 Apr 15;310(6985):955–956. doi: 10.1136/bmj.310.6985.955

Promoting cost effective prescribing.

N Freemantle, D Henry, A Maynard, G Torrance
PMCID: PMC2549355  PMID: 7728021

Full text

PDF
955

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Altman D. G. The scandal of poor medical research. BMJ. 1994 Jan 29;308(6924):283–284. doi: 10.1136/bmj.308.6924.283. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Antman E. M., Lau J., Kupelnick B., Mosteller F., Chalmers T. C. A comparison of results of meta-analyses of randomized control trials and recommendations of clinical experts. Treatments for myocardial infarction. JAMA. 1992 Jul 8;268(2):240–248. [PubMed] [Google Scholar]
  3. Freemantle N., House A., Song F., Mason J. M., Sheldon T. A. Prescribing selective serotonin reuptake inhibitors as strategy for prevention of suicide. BMJ. 1994 Jul 23;309(6949):249–253. doi: 10.1136/bmj.309.6949.249. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Freemantle N., Maynard A. Something rotten in the state of clinical and economic evaluations? Health Econ. 1994 Mar-Apr;3(2):63–67. doi: 10.1002/hec.4730030202. [DOI] [PubMed] [Google Scholar]
  5. Gøtzsche P. C. Methodology and overt and hidden bias in reports of 196 double-blind trials of nonsteroidal antiinflammatory drugs in rheumatoid arthritis. Control Clin Trials. 1989 Mar;10(1):31–56. doi: 10.1016/0197-2456(89)90017-2. [DOI] [PubMed] [Google Scholar]
  6. Hillman A. L., Eisenberg J. M., Pauly M. V., Bloom B. S., Glick H., Kinosian B., Schwartz J. S. Avoiding bias in the conduct and reporting of cost-effectiveness research sponsored by pharmaceutical companies. N Engl J Med. 1991 May 9;324(19):1362–1365. doi: 10.1056/NEJM199105093241911. [DOI] [PubMed] [Google Scholar]
  7. Hutton J., Borowitz M., Oleksy I., Luce B. R. The pharmaceutical industry and health reform: lessons from Europe. Health Aff (Millwood) 1994 Summer;13(3):98–111. doi: 10.1377/hlthaff.13.3.98. [DOI] [PubMed] [Google Scholar]
  8. Jönsson B., Bebbington P. E. What price depression? The cost of depression and the cost-effectiveness of pharmacological treatment. Br J Psychiatry. 1994 May;164(5):665–673. doi: 10.1192/bjp.164.5.665. [DOI] [PubMed] [Google Scholar]
  9. Mulrow C. D. Rationale for systematic reviews. BMJ. 1994 Sep 3;309(6954):597–599. doi: 10.1136/bmj.309.6954.597. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Williams A. The cost-benefit approach. Br Med Bull. 1974 Sep;30(3):252–256. doi: 10.1093/oxfordjournals.bmb.a071211. [DOI] [PubMed] [Google Scholar]
  12. Woolf S. H., Battista R. N., Anderson G. M., Logan A. G., Wang E. Assessing the clinical effectiveness of preventive maneuvers: analytic principles and systematic methods in reviewing evidence and developing clinical practice recommendations. A report by the Canadian Task Force on the Periodic Health Examination. J Clin Epidemiol. 1990;43(9):891–905. doi: 10.1016/0895-4356(90)90073-x. [DOI] [PubMed] [Google Scholar]

Articles from BMJ : British Medical Journal are provided here courtesy of BMJ Publishing Group

RESOURCES